Skip to main content

BeNeLuxA

Hauptnavigation

  • News
    • Joint HTA assessment on autologous gene therapy Libmeldy ongoing
    • Pharmaceutical Developments on Haemophilia
    • Pharmaceutical Developments on Alzheimer’s Disease
    • Archive
  • About
    • Beneluxa initiative
    • Mandate and organisation
    • Benefits
  • Statements
  • Activities
    • Horizon Scanning
    • Health Technology Assessment
      • HTA procedures within the Beneluxa Initiative
    • Information Sharing
      • Patient registries
    • Pricing and reimbursement
  • Documents
    • Background documents
    • Publications
    • Press releases
    • Templates
  • Contact
  • xclose
Contact
contact us
Activities
Symbolic chart
Beneluxa initiative
Map with IE

The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.

Joint HTA assessment on autologous gene therapy Libmeldy ongoing

The company Orchard Therapeutics (Netherlands) BV has stated its willingness to participate in a joint assessment of the autologous gene therapy Libmeldy (atidarsagene autotemcel) within the…
more: Joint HTA assessment on autologous gene therapy Libmeldy ongoing

Pharmaceutical Developments on Haemophilia

This report, written by the Taskforce Horizon Scanning of the Beneluxa Initiative, describes the current situation of Haemophilia and provides an overview of new pharmaceutical developments regarding…
more: Pharmaceutical Developments on Haemophilia

Pharmaceutical Developments on Alzheimer’s Disease

This report, by the Taskforce Horizon Scanning of the Beneluxa Initiative, describes the current situation of Alzheimer’s disease and provides an overview of new pharmaceutical developments regarding…
more: Pharmaceutical Developments on Alzheimer’s Disease

Contact

info@beneluxa.org

Info

Disclaimer

Links

About

Back to top